| Cat. No. : |
SOST-925H |
| Description : |
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease. |
| Source : |
Mammalian cells |
| Species : |
Human |
| Nterminal Sequence Analysis : |
His |
| Activity : |
Measured by its ability to inhibit Wnt3ainduced alkaline phosphatase production by MC3T3-E1mouse preosteoblast cells. The ED50 for this effect is typically 1.5-6μg/mL in the presence of 3ng/mL Recombinant Mouse Wnt3a. Measured by its ability to inhibit BMP6induced alkaline phosphatase production by MC3T3-E1 mouse preosteoblast cells. 30µg/mL of rhSOST will antagonize hBMP6 induction of alkaline phosphatase in MC3T3E1 cells by 5080%. |
| Structure / Form : |
Monomer |
| Predicted MolecularMass : |
22.5 kDa |
| Endotoxin Level : |
<1.0 EU per 1 μg of the protein by the LAL method |
| Purity : |
> 95% as determined by SDS-PAGE. |
| Formulation : |
Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution : |
Reconstitute at 200 μg/mL in sterile PBS. |
| Stability & Storage : |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°Cas supplied. 1 month, 2 to 8°Cunder sterile conditions after reconstitution. 3 months, -20 to -70°Cunder sterile conditions after reconstitution. |
